Previous 10 | Next 10 |
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indicatio...
SELLAS Life Sciences press release ( NASDAQ: SLS ): Q2 GAAP EPS of -$0.41 misses by $0.02 . As of June 30, 2022, cash and cash equivalents totaled approximately $27M. For further details see: SELLAS Life Sciences GAAP EPS of -$0.41 misses by $0.02
– Reported Encouraging Updated Data in Q2 from Two Clinical Trials of Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors– – Provides Clinical Update for GFH009 Program – – Cash Position of $27.0 million as of June 30, 2022 &...
SELLAS Life Sciences ( NASDAQ: SLS ) is trading 9.2% higher on Tuesday after the company announced results from preclinical studies for its CDK9 inhibitor, GFH009, to treat solid cancer and acute myeloid leukemia (AML) cell lines. The drug showed significant a...
- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines - - In Three of the Four Cell Lines, GFH009 Inhibited Cancer Growth by 90 to 100 Percent - NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc . (NASDAQ: SLS) (“...
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, toda...
Late last year, BMY broke out of a long-term range, and that break out is continuing. BMY stalled for the last few months, but its recent strong activity indicates a probable return to outperforming the second half of 2022. BMY's repurchase plan and well-covered dividend should su...
Sellas Life Sciences (NASDAQ:SLS) said on Monday no dose-limiting toxicities were observed in lymphoma and acute myeloid leukemia (AML) patients, when treated with its therapy, GFH009, in a Phase 1 trial. (SLS) rose 2.5% before the bell. In the AML group, patients treated at the 22....
- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date - - Early Indications of Efficacy in Assessable Patients at Multiple Dose Levels - NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Science...
The following slide deck was published by SELLAS Life Sciences Group, Inc. in conjunction with this event. For further details see: SELLAS Life Sciences Group (SLS) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...